Filing Analysis
Iterum Therapeutics plc has filed a petition in the High Court in Ireland to wind up the company and is withdrawing its appeal against Nasdaq delisting. The company has appointed joint provisional liquidators and expects to cease all future SEC filings, including its 2025 Annual Report.
🚩 Red Flags
- Winding up petition (liquidation) filed in Ireland.
- Immediate delisting from Nasdaq following withdrawal of appeal.
- Cessation of all future SEC reporting obligations.
- Appointment of provisional liquidators to oversee the dissolution of the company.
- Explicit statement regarding limited cash resources.
📋 Key Facts
- Filed a petition in the High Court in Ireland to wind up the company on March 27, 2026.
- Withdrew appeal of Nasdaq delisting determination on March 30, 2026.
- Trading of ordinary shares will be suspended on Nasdaq at the opening of business on April 1, 2026.
- Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited appointed as joint provisional liquidators.
- Company stated it does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or any future SEC filings.
- The company cited 'limited cash resources' as a primary driver for the winding up process.
Iterum Therapeutics plc has filed a petition in the High Court in Ireland to wind up the company and has appointed Joint Provisional Liquidators. This action has triggered an immediate resignation of the CEO and CFO, an event of default on its Royalty-Linked Subordinated Notes, and an expected total loss for shareholders.
🚩 Red Flags
- Liquidation/Winding up petition filed.
- Immediate resignation of the entire top executive suite (CEO and CFO).
- Event of default on debt obligations.
- Warning of total loss for equity holders.
- Imminent delisting from Nasdaq.
📋 Key Facts
- Filed a Winding Up Petition in the High Court in Ireland on March 27, 2026.
- Damien Murran and Jennifer McMahon of Teneo Restructuring appointed as Joint Provisional Liquidators.
- CEO Corey Fishman and CFO Judith Matthews resigned effective March 27, 2026.
- The filing triggered an event of default on the company's Limited Recourse Royalty-Linked Subordinated Notes dated January 21, 2020.
- Default interest on the notes is now Prime + 3%.
- Nasdaq trading suspension expected to be effective as of March 27, 2026.
- Company warns securityholders to expect a 'significant or complete loss on their investment'.
Iterum Therapeutics requested a hearing to appeal a Nasdaq delisting notice regarding its failure to maintain a $1.00 minimum bid price. The company also disclosed non-compliance with the $35 million minimum market value requirement and warned of a potential wind-down or bankruptcy where shareholders would likely receive no return.
🚩 Red Flags
- Explicit warning that shareholders are 'very unlikely to receive any meaningful distribution' in a potential liquidation.
- Multiple Nasdaq non-compliance issues (bid price and $35M market value).
- Company admits to 'limited ability to raise additional capital' and 'limited time and available resources'.
- Possibility of a wind-down or bankruptcy filing explicitly mentioned.
📋 Key Facts
- Received Nasdaq delisting determination letter on February 24, 2026, due to failure to maintain $1.00 minimum bid price.
- Requested a hearing before the Nasdaq Hearings Panel on March 3, 2026, which stays the delisting action temporarily.
- Currently fails to meet Nasdaq Listing Rule 5550(b)(2) requiring a minimum market value of listed securities of $35 million.
- Compliance deadline for the $35 million market value requirement is June 9, 2026.
- Management is evaluating strategic alternatives including licensing, sale, or a potential bankruptcy/liquidation proceeding.
Iterum Therapeutics received a Nasdaq delisting determination letter on February 24, 2026, due to continued non-compliance with the $1.00 minimum bid price rule. The company's shares are scheduled for suspension on March 5, 2026, and management is openly discussing the possibility of bankruptcy, liquidation, or a total wind-down of operations.
🚩 Red Flags
- Imminent delisting and suspension of trading on Nasdaq.
- Explicit mention of potential bankruptcy, liquidation, or dissolution.
- Warning of total loss for shareholders.
- Potential filing of Form 15 to cease SEC reporting obligations.
- Limited ability to raise additional capital.
📋 Key Facts
- Nasdaq issued a delisting determination letter on February 24, 2026.
- Trading suspension is scheduled for the open of business on March 5, 2026.
- The company is non-compliant with the $1.00 minimum bid price rule (Rule 5550(a)(2)).
- The company is also non-compliant with the $35 million Minimum Market Value of Listed Securities (MVLS) requirement.
- Management stated that shareholders are 'very unlikely to receive any meaningful distribution or return' in a potential liquidation.
Iterum Therapeutics plc shareholders rejected all four major proposals at an Extraordinary General Meeting (EGM), including capital increases and a reverse stock split. This failure severely restricts the company's ability to raise capital, significantly increasing the risk of bankruptcy or liquidation.
🚩 Red Flags
- Going concern language explicitly stated: 'ability to continue as a going concern are likely to be materially and adversely affected'.
- Explicit mention of potential bankruptcy, liquidation, dissolution, or winding down of operations.
- Shareholder rejection of all capital-raising mechanisms (capital increase and allotment authority).
- Rejection of reverse stock split, which is often used to maintain Nasdaq compliance/listing status.
- Warning that shareholders are 'very unlikely to receive any meaningful distribution' in a liquidation scenario.
📋 Key Facts
- Shareholders voted 'Against' Proposal 1: Increase authorized share capital from $1.8M to $2.3M (50M additional shares).
- Shareholders voted 'Against' Proposal 2: Granting Board authority to allot/issue shares, warrants, or options.
- Shareholders voted 'Against' Proposal 3: Opt-out of pre-emption rights for cash issuances.
- Shareholders voted 'Against' Proposal 4: A reverse stock split (consolidation ratio between 10:1 and 15:1).
- The company is evaluating strategic alternatives including licensing, sale, divestiture, or wind-down.
Iterum Therapeutics plc received a notice from Nasdaq stating it is non-compliant with the Minimum Market Value of Listed Securities (MVLS) requirement after falling below $35 million for 30 consecutive business days. The company has been granted a compliance period until June 9, 2026, to regain compliance.
🚩 Red Flags
- Delisting notice regarding Minimum Market Value of Listed Securities (MVLS)
- Existing non-compliance with the $1.00 minimum bid price rule
- Failure to meet shareholder equity and net income standards
- Potential for a reverse stock split to maintain listing status
📋 Key Facts
- Received Nasdaq notice on December 11, 2025, regarding non-compliance with Nasdaq Listing Rule 5550(b)(2) (Minimum MVLS of $35 million).
- MVLS has been below the $35 million threshold for the last 30 consecutive business days.
- Company is also currently out of compliance with the $1.00 minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)).
- Compliance deadline for MVLS requirement: June 9, 2026.
- Compliance deadline for Bid Price Rule: February 23, 2026 (with potential for a second 180-day extension if other requirements are met).
- The company may need to effect a reverse stock split to satisfy the Bid Price Rule during a potential second compliance period.
Iterum Therapeutics plc has filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the earnings press release issued on November 14, 2025.
📋 Key Facts
- Report date: November 14, 2025
- Reporting period: Third quarter ended September 30, 2025
- The filing includes a press release as Exhibit 99.1
- Information is furnished but not 'filed' under Section 18 of the Exchange Act.
Iterum Therapeutics plc announced an at-the-market (ATM) offering to sell up to $20 million in ordinary shares under its existing S-3 registration statement. The company also provided a business update regarding the recent commercial launch of ORLYNVAH™.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of up to ~21.7 million shares.
- Reliance on capital markets (ATM offering) to fund operations, as noted in forward-looking statements regarding the ability to raise funds.
📋 Key Facts
- The company is offering up to $20,000,000 in additional aggregate gross proceeds via an ATM offering.
- The offering involves up to 21,756,057 ordinary shares.
- H.C. Wainwright & Co., LLC is acting as the sales agent under a Sales Agreement dated October 7, 2022.
- ORLYNVAH™ was commercially launched in the U.S. community market in August 2025.
- The company expects modest sales for ORLYNVAH™ during the remainder of 2025.
Iterum Therapeutics plc held its 2025 Annual General Meeting (AGM) where shareholders rejected several critical capital-raising and governance proposals. While one director was elected and the auditor was ratified, the rejection of share capital increases and pre-emption rights opt-outs significantly limits management's ability to raise equity.
🚩 Red Flags
- Significant shareholder revolt: Rejection of Proposals 3 through 7 indicates deep dissatisfaction with management/governance.
- Capital constraints: The rejection of Proposal 4 and Proposal 5 severely restricts the company's ability to issue new equity for fundraising.
- Pre-emption rights restriction: Failure to pass Proposal 6 means any future equity issuance must offer shares to existing shareholders first, which can complicate rapid capital raises.
- Inability to expand incentive pool: Rejection of Proposal 7 limits the use of equity as compensation for talent.
📋 Key Facts
- David Kelly was elected to the Board of Directors (Class I) for a three-year term expiring in 2028.
- Shareholders ratified the appointment of KPMG as independent auditor for fiscal year 2025.
- Proposal 3: Shareholders did not approve the advisory vote on executive compensation (Say-on-Pay).
- Proposal 4: Shareholders rejected an increase in authorized share capital from $1.8M to $2.6M (80,000,000 shares).
- Proposal 5: Shareholders rejected authority for directors to allot and issue shares/warrants.
- Proposal 6: Shareholders rejected a pre-emption rights opt-out proposal (which required a 75% supermajority).
- Proposal 7: Shareholders rejected an amendment to increase the Equity Incentive Plan by 4,000,000 shares.
Iterum Therapeutics plc received a notice from Nasdaq stating it is non-compliant with the minimum $1.00 bid price rule after failing to maintain that price for 30 consecutive business days. The company has until February 23, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(a)(2))
- Potential for a mandatory reverse stock split to regain compliance
- Failure to maintain minimum bid price indicates significant downward pressure on share price
📋 Key Facts
- Received notice from Nasdaq on August 25, 2025, regarding non-compliance with Nasdaq Listing Rule 5550(a)(2).
- The deficiency is based on the closing bid price being below $1.00 for the last 30 consecutive business days.
- The company has a 180-day compliance period ending February 23, 2026.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days.
- A second 180-day extension may be available if market value requirements are met and a reverse split is used to cure the deficiency.
Iterum Therapeutics plc announced the U.S. commercial launch of ORLYNVAH™ oral tablets for treating uncomplicated urinary tract infections (uUTIs) in adult women. This marks a significant transition from clinical development to commercial-stage operations.
📋 Key Facts
- Product Name: ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets.
- Indication: Treatment of adult women with uncomplicated urinary tract infections (uUTIs) caused by E. coli, K. pneumoniae, or P. mirabilis.
- Market Position: Targeted at patients with limited or no alternative oral antibacterial options.
- Event Date: August 20, 2025.
Iterum Therapeutics plc filed an 8-K to furnish its second quarter 2025 financial results (ended June 30, 2025) via a press release. The filing is for informational purposes and does not contain substantive changes to corporate structure or material agreements.
📋 Key Facts
- Report date: August 5, 2025
- Reporting period: Second quarter ended June 30, 2025
- The filing furnishes a press release (Exhibit 99.1) regarding financial results.
- Information is furnished but not 'filed' for purposes of Section 18 liability.
Iterum Therapeutics plc entered into a five-year Commercial Manufacturing and Supply Agreement with ACS Dobfar S.p.A for the manufacture and supply of its approved product, ORLYNVAH bilayer tablets.
📋 Key Facts
- Agreement effective date: July 29, 2025
- Counterparty: ACS Dobfar S.p.A (and affiliates)
- Products: ORLYNVAH bilayer tablets and/or sulopenem etzadroxil bulk drug substance
- Term: Initial five-year term with a two-year automatic renewal period
- Pricing structure: Per kilogram or per bottle of tablets, subject to potential cost reduction adjustments
- Supply mechanism: Based on rolling forecasts with binding firm orders
Iterum Therapeutics plc has announced the date for its 2025 Annual General Meeting of Shareholders, scheduled for September 10, 2025. The filing also establishes deadlines for shareholder proposals and director nominations in accordance with Rule 14a-8.
📋 Key Facts
- The 2025 Annual Meeting is set for September 10, 2025.
- The record date for determining voting shareholders was July 15, 2025.
- The deadline for receipt of shareholder proposals under Rule 14a-8 is July 28, 2025.
- The deadline for notice of director nominations or other proposals under the Company's Constitution is also July 28, 2025.
Iterum Therapeutics US Limited entered into a Product Commercialization Agreement with EVERSANA Life Science Services, LLC for the commercialization of its approved product, ORLYNVAH™, in the United States. Eversana will provide comprehensive sales, marketing, logistics, and regulatory services.
🚩 Red Flags
- Termination clause triggered by a decline in net sales over a specified period, which could impact service continuity if commercial performance is weak.
📋 Key Facts
- Agreement date: June 6, 2025
- Counterparty: EVERSANA Life Science Services, LLC
- Product: ORLYNVAH™ (approved product)
- Scope of services: Sales and commercial operations, marketing, logistics, channel management, regulatory, and medical affairs in the US.
- Term: From execution until five years after the date of commercial launch of ORLYNVAH™.
- Exclusivity: Eversana will serve as the exclusive provider for the agreed-upon services.
- Financial terms: ITUS to pay fees and reimburse expenses per applicable statements of work.
Iterum Therapeutics has amended its promissory note with Pfizer to extend the deferral period for a $20 million milestone payment from 2026 to October 25, 2029. In exchange for this extension, the interest rate on the note will increase from 8% to 10% starting in late 2026.
🚩 Red Flags
- Increased cost of capital: The interest rate hike (8% to 10%) increases the long-term debt burden.
- Restrictive Covenants: ITIL is restricted from incurring senior debt or granting liens without Pfizer's consent, which may limit future financing flexibility.
- Change of Control Trigger: A change in control of Iterum or ITIL allows Pfizer to demand immediate payment of the $20M plus interest.
📋 Key Facts
- The $20 million milestone payment was triggered by FDA approval of ORLYNVAH (sulopenem etzadroxil and probenecid) on October 25, 2024.
- The deferral period has been extended from the original expiration of October 25, 2026, to October 25, 2029.
- Interest rate increases from 8% to 10% on a daily compounded basis beginning October 26, 2026.
- ITIL must pay Pfizer non-refundable transaction fees and documented legal expenses related to the amendment.
- The Company has placed restrictive covenants on ITIL regarding senior indebtedness and liens on assets.
Iterum Therapeutics plc filed an 8-K to furnish its quarterly press release announcing financial results for the first quarter ended March 31, 2025. The filing is a standard earnings announcement and does not contain substantive material changes or corporate actions.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: First Quarter ended March 31, 2025
- The filing is for the purpose of furnishing results via press release (Exhibit 99.1)
- Information is furnished but not 'filed' under Section 18 of the Exchange Act.
Iterum Therapeutics plc entered into a securities purchase agreement for a registered direct offering of ordinary shares and pre-funded warrants to raise approximately $5.0 million in gross proceeds. The company intends to use the net proceeds (~$4.2 million) to extend its cash runway into 2026 to support strategic alternatives or the commercial launch of ORLYNVAH™.
🚩 Red Flags
- Dilutive offering: Issuance of significant new shares and warrants at a low price point.
- Liquidity pressure: The company is raising capital specifically to extend runway into 2026, indicating current cash levels are insufficient for long-term operations without further dilution.
- Going concern risk mentioned in forward-looking statements regarding the ability to continue as a going concern.
📋 Key Facts
- Gross proceeds from the offering: approximately $5.0 million.
- Net proceeds expected: approximately $4.2 million after fees and expenses.
- Offering structure: 3,040,000 ordinary shares at $0.90/share and up to 2,515,556 pre-funded warrants at $0.89/warrant.
- Pre-funded warrants are immediately exercisable at $0.01 per share.
- Warrants include a 9.99% ownership cap for the purchaser.
- H.C. Wainwright & Co., LLC is acting as placement agent with an 8.5% total fee (7.5% cash + 1.0% management).
- Expected closing date: on or about April 30, 2025.
Iterum Therapeutics plc has appointed Joseph J. Whalen to the Board and Audit/Compensation committees to restore Nasdaq compliance regarding audit committee independence. Additionally, David Kelly has been named Chairman following the resignation of Ronald M. Hunt.
🚩 Red Flags
- Recent resignation of Chairman Ronald M. Hunt (Feb 14, 2025) triggered a need for structural changes.
- The company was previously non-compliant with Nasdaq audit committee independence requirements.
📋 Key Facts
- Joseph J. Whalen appointed to the Board effective March 10, 2025.
- Whalen will serve on the Audit Committee and Compensation Committee.
- Whalen's appointment restores Nasdaq compliance with Listing Rule 5605(c)(2)(A) regarding audit committee independence.
- David Kelly appointed Chairman of the Board effective March 10, 2025.
- Former Chairman Ronald M. Hunt resigned from the Board on February 14, 2025.
- Whalen's compensation includes a $35,000 annual cash retainer for board service and additional fees for committee roles.
Iterum Therapeutics plc notified Nasdaq that it is no longer in compliance with audit committee requirements due to the immediate resignation of Chairman Ronald Hunt. This vacancy leaves the company's Audit Committee without sufficient members to meet Nasdaq Listing Rule 5605(c)(2)(A).
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules
- Immediate departure of a key Board member (Chairman)
- Loss of Audit Committee composition requirements
📋 Key Facts
- Ronald Hunt resigned as Chairman and Director effective February 14, 2025.
- The resignation resulted in a failure to comply with Nasdaq Listing Rule 5605(c)(2)(A) regarding audit committee requirements.
- Mr. Hunt served on the Audit Committee, Compensation and Nominating Committee, and Corporate Governance Committee.
- The company stated the resignation was not due to any disagreement or dispute regarding operations, policies, or practices.
Iterum Therapeutics plc issued an 8-K to furnish its press release announcing financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: February 7, 2025
- Reporting period: Q4 and Full Year ended December 31, 2024
- The filing is for the purpose of furnishing financial results via Exhibit 99.1
- Information is furnished but not 'filed' under Section 18 of the Exchange Act
Iterum Therapeutics plc has filed a prospectus supplement to its existing S-3 registration statement to facilitate the sale of ordinary shares for up to $25.0 million via an at-the-market (ATM) offering agreement with H.C. Wainwright & Co., LLC.
🚩 Red Flags
- Dilutive event: The issuance of new ordinary shares will dilute existing shareholders.
- Continuous financing pattern: Multiple prospectus supplements filed in October and December 2024 suggest a high burn rate or ongoing need for liquidity.
📋 Key Facts
- The company is increasing its aggregate gross proceeds capacity under the existing Sales Agreement by up to $25.0 million.
- The offering will be conducted via an 'at-the-market' (ATM) mechanism.
- H.C. Wainwright & Co., LLC is serving as the sales agent.
- Prior sales under this agreement and related prospectus supplements have already generated approximately $16.0 million in gross proceeds.
- The offering is being made under an existing effective registration statement on Form S-3 (File No. 333-267795).
Iterum Therapeutics plc has successfully cured its deficiency under Nasdaq Listing Rule 5550(b). The company is now in compliance with continued listing requirements, and the previously scheduled hearing before the Hearings Panel has been cancelled.
🚩 Red Flags
- Previous non-compliance with Nasdaq listing rules (Rule 5550(b)) which posed a delisting risk.
📋 Key Facts
- Received a letter from Nasdaq Listing Qualifications Staff on November 20, 2024.
- Deficiency under Listing Rule 5550(b) has been officially cured.
- The company is in compliance with applicable continued listing requirements.
- The Hearings Panel hearing scheduled for November 21, 2024, was cancelled.
- Company will continue to be traded on The Nasdaq Capital Market.
Iterum Therapeutics plc filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2024. The filing serves as a formal announcement of the release of their quarterly earnings press release.
📋 Key Facts
- Reporting date: November 14, 2024
- Period covered: Third quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the earnings press release
- Information is furnished but not 'filed' under Section 18 of the Exchange Act
Iterum Therapeutics plc announced the FDA approval of ORLYNVAH™ for uncomplicated urinary tract infections and subsequently elected to defer a $20.0 million milestone payment to Pfizer Inc. by issuing a promissory note.
🚩 Red Flags
- Creation of a $20 million direct financial obligation via promissory note.
- Acceleration clause: A change of control could trigger immediate repayment of the $20M plus interest, potentially impacting M&A prospects or liquidity.
📋 Key Facts
- FDA approved ORLYNVAH™ (sulopenem etzadroxil and probenecid) on October 25, 2024.
- The Company elected to defer the $20.0 million milestone payment for two years under the Pfizer License Agreement.
- A promissory note was issued by ITIL to Pfizer maturing on October 25, 2026.
- The Note bears an annual interest rate of 8% on a daily compounded basis.
- Pfizer has the option to accelerate the debt (make it immediately due) if a change of control occurs during the deferral period.
Iterum Therapeutics announced FDA approval for its first product, ORLYNVAH™, for the treatment of uncomplicated urinary tract infections (uUTIs). Concurrently, the company is actively seeking a strategic transaction, such as a sale, partnership, or licensing arrangement, to maximize stakeholder value.
🚩 Red Flags
- Explicit mention that the ability to execute strategic alternatives depends on 'the Company's ability to raise sufficient capital to fund operations'.
- Uncertainty regarding the outcome and timing of the strategic review process.
- Potential for significant dilution or liquidation if a sale is not achieved and capital cannot be raised.
📋 Key Facts
- FDA approved ORLYNVAH™ (sulopenem etzadroxil and probenecid) for uUTIs in adult women with limited/no alternative oral antibacterial options.
- Approval based on Phase 3 trials SURE 1 (superiority to ciprofloxacin in fluoroquinolone-resistant infections) and REASSURE (non-inferiority/superiority to Augmentin).
- The company is engaged in a strategic review process involving an investment bank to explore sale, partnership, or licensing of ORLYNVAH™.
- If no transaction is reached, the company may pursue direct commercialization via a targeted sales force, subject to capital availability.
Iterum Therapeutics plc has received a delisting determination from Nasdaq after failing to meet the minimum $2,500,000 stockholders' equity requirement. The company has requested an oral hearing with the Nasdaq Hearings Panel, which is scheduled for November 21, 2024.
🚩 Red Flags
- Delisting notice/non-compliance with minimum stockholders' equity requirement.
- Failure to meet previously granted extension deadline (September 30, 2024).
- Uncertainty regarding the ability to regain compliance or secure an additional extension.
📋 Key Facts
- Nasdaq issued a delisting determination letter on October 1, 2024, after the company failed to meet extension terms.
- The company failed to comply with Nasdaq Listing Rule 5550(b) regarding the $2.5M minimum stockholders' equity requirement.
- An oral hearing before the Nasdaq Hearings Panel is scheduled for November 21, 2024.
- Trading of ITRM shares remains active on the Nasdaq Capital Market pending the outcome of the hearing due to a stay of suspension.
Iterum Therapeutics plc shareholders approved a proposal granting the Board of Directors authority to issue ordinary shares for cash without first offering them to existing shareholders (waiving pre-emptive rights). This move facilitates rapid capital raising through direct allotments.
🚩 Red Flags
- Approval of share issuance without pre-emptive rights can lead to significant dilution for existing shareholders.
- The ability to issue shares directly to specific parties (often preferred in private placements) is a common precursor to rapid capital infusion needed by cash-burning biotech firms.
📋 Key Facts
- Extraordinary general meeting held on October 8, 2024.
- Shareholders approved the authority to allot shares for cash without first offering them to existing shareholders under Irish law.
- The proposal required a 75% affirmative vote threshold.
- Voting results: 9,785,120 'For', 3,103,525 'Against', and 133,633 'Abstain'.
Iterum Therapeutics plc received a delisting determination letter from Nasdaq on October 1, 2024, after failing to meet the minimum $2.5 million stockholders' equity requirement by the September 30, 2024 deadline. The company plans to request a hearing with the Nasdaq Hearings Panel to stay the delisting action.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules
- Failure to meet minimum stockholders' equity requirement ($2.5M)
- Expiration of previous compliance extension
📋 Key Facts
- Nasdaq issued a delisting determination letter on October 1, 2024.
- The company failed to comply with Nasdaq Listing Rule 5550(b) regarding the $2.5 million minimum stockholders' equity requirement.
- An extension previously granted by Nasdaq expired on September 30, 2024.
- The company intends to submit a hearing request to the Nasdaq Hearings Panel to stay delisting.
- Shares will continue to trade under symbol 'ITRM' pending the outcome of the hearing process.
- A potential extension from the Panel could last until March 31, 2025.
Iterum Therapeutics plc filed an 8-K to furnish its second quarter 2024 financial results as a press release. The filing does not contain substantive new material agreements or structural changes, but rather serves as the formal mechanism for disclosing quarterly earnings.
📋 Key Facts
- Report date: August 14, 2024
- Reporting period: Second quarter ended June 30, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
- Information is furnished but not 'filed' for purposes of Section 18 liability.
Iterum Therapeutics plc announced the expiration of its previously announced rights offering subscription period on August 6, 2024. The filing serves to communicate the results of the offering via an attached press release.
🚩 Red Flags
- Rights offerings in micro-cap biotech companies are often used to raise necessary capital to extend cash runway, which can lead to significant shareholder dilution.
📋 Key Facts
- The subscription period for the rights offering expired at 5:00 p.m. ET on August 6, 2024.
- Results of the rights offering are detailed in Exhibit 99.1.
- The company is an Irish-domiciled entity (Iterum Therapeutics plc) trading on Nasdaq under ticker ITRM.
Iterum Therapeutics plc announced the commencement of its previously disclosed subscription rights offering on July 22, 2024. This is a capital raising event intended to provide existing shareholders the opportunity to purchase additional shares.
🚩 Red Flags
- Subscription rights offerings are often used by micro-cap companies to raise necessary liquidity, which can signal a need for immediate cash to fund operations.
📋 Key Facts
- Commencement date: July 22, 2024
- Type of offering: Subscription rights offering
- The announcement was made via press release (Exhibit 99.1)
Iterum Therapeutics plc has set a record date of July 16, 2024, for a proposed rights offering to issue 8,503,800 units at $1.21 per unit. The offering includes ordinary shares and two tranches of warrants (1-year and 5-year terms).
🚩 Red Flags
- Dilutive offering: The inclusion of significant warrant tranches (1-year and 5-year) will lead to substantial future dilution.
- Going concern risk mentioned in forward-looking statements regarding the sufficiency of cash resources.
- Potential for non-participation by small shareholders due to rounding/minimum exercise requirements.
📋 Key Facts
- Record Date: July 16, 2024.
- Subscription Period: Expected to begin on or about July 22, 2024, for at least 14 days.
- Expiration Date: Currently expected to be August 6, 2024.
- Offering Size: 8,503,800 Units.
- Unit Price: $1.21 per unit (consisting of one ordinary share and two warrants).
- Warrant Structure: One 1-year warrant to purchase 0.5 shares and one 5-year warrant to purchase 1 share at $1.21 exercise price.
- Subscription Right Price: $0.605 per 0.50 Units (effective rate of $1.21 per unit).
- One holder of eligible warrants for 56,606 shares has already waived their right to participate.
Iterum Therapeutics held its 2024 Annual General Meeting (AGM) resulting in the election of two new directors and ratification of KPMG as auditors. Additionally, the company announced that the FDA will hold an Advisory Committee meeting on September 9, 2024, regarding the NDA for oral sulopenem.
🚩 Red Flags
- FDA Advisory Committee meetings introduce significant regulatory uncertainty regarding potential drug approval.
📋 Key Facts
- Corey Fishman and Ronald Hunt were elected to the Board of Directors for three-year terms expiring in 2027.
- Shareholders ratified KPMG as the independent registered public accounting firm for fiscal year 2024.
- The FDA scheduled an Advisory Committee meeting for September 9, 2024, regarding sulopenem etzadroxil/probenecid (oral sulopenem) for uUTIs.
- The FDA's focus for the committee includes antimicrobial stewardship and defining the appropriate target patient population.
Iterum Therapeutics received a 180-day extension from Nasdaq to regain compliance with minimum stockholders' equity requirements, providing until September 30, 2024. Additionally, the company announced that the FDA has assigned a PDUFA action date of October 25, 2024, for its oral sulopenem NDA resubmission.
🚩 Red Flags
- Delisting risk: Failure to meet equity requirements by Sept 30, 2024, may lead to delisting.
- Negative stockholders' equity of ($6.4M) significantly below Nasdaq minimums.
- Officer departure (CMO resignation), though mitigated by a consulting agreement.
📋 Key Facts
- Nasdaq granted a 180-day extension to evidence compliance with Rule 5550(b)(1) until September 30, 2024.
- The company's stockholders' equity deficit was ($6,403,000) as of December 31, 2023, failing the $2.5M minimum requirement.
- Chief Medical Officer Dr. Sailaja Puttagunta is transitioning from CMO to a consultant at a rate of $400 per hour effective June 1, 2024.
- The FDA assigned a PDUFA action date of October 25, 2024, for the oral sulopenem NDA resubmission (Class II review).
- The CMO's consulting role is specifically to support the regulatory review period.
Iterum Therapeutics plc filed an 8-K to furnish its quarterly earnings press release for the first quarter ended March 31, 2024. This is a routine regulatory filing used to communicate financial results and operational updates to the market.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024
- Filing date: May 13, 2024
- The report contains an earnings press release as Exhibit 99.1
- Information is furnished but not 'filed' for purposes of Section 18 liability
Iterum Therapeutics plc announced the resignation of its Chief Medical Officer, Sailaja Puttagunta M.D., effective May 31, 2024. Dr. Puttagunta will remain as a consultant to support the regulatory review of the company's oral sulopenem NDA.
🚩 Red Flags
- Departure of a key C-suite officer (CMO) during a critical regulatory review period for the company's primary drug candidate (oral sulopenem).
📋 Key Facts
- Sailaja Puttagunta M.D. resigned as Chief Medical Officer on May 8, 2024.
- Resignation is effective May 31, 2024.
- The resignation is for personal reasons and not due to any disagreement with the Company.
- Dr. Puttagunta will serve as a consultant during the regulatory review period of the oral sulopenem NDA.
- Steven Aronin, M.D., SVP and Head of Clinical Development, will lead development and regulatory activities post-departure.
Iterum Therapeutics plc announced the resubmission of its New Drug Application (NDA) to the FDA for oral sulopenem in treating uncomplicated urinary tract infections (uUTI) in adult women.
📋 Key Facts
- Resubmitted NDA for sulopenem etzadroxil/probenecid (oral sulopenem) on April 29, 2024.
- Target indication: treatment of uncomplicated urinary tract infections (uUTI) in adult women.
- The announcement was made via a press release incorporated by reference as Exhibit 99.1.
Iterum Therapeutics plc received a deficiency notice from Nasdaq for failing to meet minimum stockholders' equity requirements. The company has until May 20, 2024, to submit a compliance plan to avoid potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules
- Negative stockholders' equity ($6.4M deficit)
- Failure to meet alternative listing standards (market value and net income)
📋 Key Facts
- Received Nasdaq deficiency letter on April 3, 2024.
- Non-compliance with Nasdaq Listing Rule 5550(b)(1) due to stockholders' equity deficit of ($6,403,000) as of Dec 31, 2023.
- The company failed the alternative standards for market value of listed securities and net income from continuing operations.
- Deadline to submit a compliance plan is May 20, 2024.
- If a plan is accepted, the company has up to 180 days (until September 30, 2024) to regain compliance.
Iterum Therapeutics plc filed an 8-K to furnish its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal announcement of the company's quarterly earnings press release.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- The filing includes Exhibit 99.1 (Press Release) as part of the disclosure
- Information is furnished but not 'filed' for purposes of Section 18 liability
Iterum Therapeutics announced an accelerated timeline for resubmitting its NDA for oral sulopenem to the FDA in Q2 2024, while simultaneously announcing it is engaging a financial advisor to evaluate strategic alternatives. The company expects current cash reserves and ATM proceeds to fund operations into 2025.
🚩 Red Flags
- Engagement of financial advisor to evaluate 'strategic alternatives' often signals potential sale or distress-driven restructuring.
- Heavy reliance on 'at-the-market' (ATM) equity offerings to extend cash runway indicates significant dilution and capital constraints.
- The company is working against a deadline to address 2021 FDA deficiencies, creating high regulatory execution risk.
📋 Key Facts
- NDA resubmission for oral sulopenem expected in the first half of Q2 2024, earlier than previously planned.
- FDA review action is anticipated approximately six months after resubmission (estimated H2 2024).
- Company expects to engage a financial advisor in the near-term to evaluate strategic alternatives (sale, license, or disposal of sulopenem rights).
- Cash and short-term investments as of Dec 31, 2023, plus ATM proceeds through Feb 29, 2024, are expected to fund operations into 2025.
- The company must address deficiencies from a July 2021 Complete Response Letter (CRL) for the NDA resubmission to be successful.
Iterum Therapeutics plc held an extraordinary general meeting where shareholders rejected a proposal to grant the Board authority to issue 5,000,000 ordinary shares for cash without first offering them to existing shareholders. The proposal failed to meet the required 75% affirmative vote threshold.
🚩 Red Flags
- Shareholder rejection of capital raising authority: The failure to secure pre-emptive waiver suggests shareholders are wary of potential dilution or lack confidence in the Board's ability to deploy cash effectively without existing shareholder participation.
📋 Key Facts
- Extraordinary General Meeting held on January 30, 2024.
- Proposal: Board authority to issue up to 5,000,000 ordinary shares for cash without pre-emptive rights (allotment of shares).
- Voting results: 3,139,498 votes 'For', 2,724,101 votes 'Against'.
- The proposal required a supermajority of at least 75% of the votes cast to pass.
- The proposal was defeated as it failed to reach the 75% threshold.
Iterum Therapeutics announced positive topline results from its Phase 3 REASSURE clinical trial for oral sulopenem, demonstrating statistical superiority over Augmentin in treating uncomplicated urinary tract infections (uUTI). Following these results, the company plans to resubmit its New Drug Application (NDA) to the FDA in Q2 2024 and simultaneously pursue a strategic sale or licensing of the drug's rights.
🚩 Red Flags
- Strategic pivot toward sale/liquidation: The company explicitly stated it plans to focus on selling or licensing the asset rather than commercializing it independently.
- Regulatory history: Previous Complete Response Letter (CRL) received in July 2021 must be successfully addressed.
📋 Key Facts
- Phase 3 REASSURE trial met primary endpoint: oral sulopenem showed 61.7% overall response vs. 55.0% for Augmentin®.
- Trial results demonstrated statistical superiority as the lower limit of the 95% confidence interval was above zero.
- Safety profile was favorable with <1% discontinuation due to adverse events and no drug-related serious adverse events (SAEs).
- Company expects to resubmit NDA in Q2 2024, with potential FDA action by Q4 2024 if deficiencies from the July 2021 CRL are addressed.
- The company is initiating a strategic process to sell, license, or dispose of sulopenem rights to maximize stakeholder value.